| scholarly article | Q13442814 |
| P50 | author | John Q. Trojanowski | Q6253636 |
| P2093 | author name string | Matthew J Winton | |
| Linda K Kwong | |||
| Virginia M-Y Lee | |||
| Lionel M Igaz | |||
| Margaret M Wong | |||
| P2860 | cites work | Isolation and characterization of the active cDNA of the human cell cycle gene (RCC1) involved in the regulation of onset of chromosome condensation | Q24299576 |
| Polyglutamine expansion of huntingtin impairs its nuclear export | Q24338269 | ||
| Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis | Q28131672 | ||
| Monoclonal antibody characterization of the C proteins of heterogeneous nuclear ribonucleoprotein complexes in vertebrate cells | Q28263029 | ||
| Leptomycin B inhibition of signal-mediated nuclear export by direct binding to CRM1 | Q28277890 | ||
| Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria | Q29614410 | ||
| TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis | Q29615597 | ||
| Expression of microtubule-associated protein 2 by reactive astrocytes | Q30454181 | ||
| Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease | Q33955976 | ||
| Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43. | Q34601207 | ||
| Frontotemporal dementia: a review. | Q34657028 | ||
| Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies | Q35607253 | ||
| TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions | Q35928153 | ||
| Nucleocytoplasmic recycling of the nuclear localization signal receptor alpha subunit in vivo is dependent on a nuclear export signal, energy, and RCC1 | Q36273838 | ||
| Structural diversity and functional implications of the eukaryotic TDP gene family | Q40608660 | ||
| TDP-43 pathology in familial frontotemporal dementia and motor neuron disease without Progranulin mutations | Q42509587 | ||
| Differential detergent treatment allows immunofluorescent localization of the Newcastle disease virus matrix protein within the nucleus of infected cells | Q44451043 | ||
| Human, Drosophila, and C.elegans TDP43: nucleic acid binding properties and splicing regulatory function | Q46434717 | ||
| Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. | Q48183466 | ||
| TDP-43-positive white matter pathology in frontotemporal lobar degeneration with ubiquitin-positive inclusions | Q48244352 | ||
| TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation | Q48255479 | ||
| P433 | issue | 19 | |
| P407 | language of work or name | English | Q1860 |
| P1104 | number of pages | 8 | |
| P304 | page(s) | 13302-13309 | |
| P577 | publication date | 2008-02-27 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation | |
| P478 | volume | 283 |
| Q34998181 | A "two-hit" hypothesis for inclusion formation by carboxyl-terminal fragments of TDP-43 protein linked to RNA depletion and impaired microtubule-dependent transport |
| Q58698146 | A feedback loop between dipeptide-repeat protein, TDP-43 and karyopherin-α mediates C9orf72-related neurodegeneration |
| Q30570770 | A high-content screen identifies novel compounds that inhibit stress-induced TDP-43 cellular aggregation and associated cytotoxicity. |
| Q41908807 | A molecular mechanism realizing sequence-specific recognition of nucleic acids by TDP-43. |
| Q37036144 | A novel Drosophila model of TDP-43 proteinopathies: N-terminal sequences combined with the Q/N domain induce protein functional loss and locomotion defects |
| Q24632492 | A seeding reaction recapitulates intracellular formation of Sarkosyl-insoluble transactivation response element (TAR) DNA-binding protein-43 inclusions |
| Q30482763 | A90V TDP-43 variant results in the aberrant localization of TDP-43 in vitro |
| Q35605176 | ALS mutations in FUS cause neuronal dysfunction and death in Caenorhabditis elegans by a dominant gain-of-function mechanism |
| Q35886826 | ALS-Causing Mutations Significantly Perturb the Self-Assembly and Interaction with Nucleic Acid of the Intrinsically Disordered Prion-Like Domain of TDP-43. |
| Q27301374 | ALS-associated TDP-43 induces endoplasmic reticulum stress, which drives cytoplasmic TDP-43 accumulation and stress granule formation |
| Q24630100 | ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import |
| Q30536540 | ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. |
| Q50930970 | ALS/FTLD-linked TDP-43 regulates neurite morphology and cell survival in differentiated neurons. |
| Q36873601 | Aberrant assembly of RNA recognition motif 1 links to pathogenic conversion of TAR DNA-binding protein of 43 kDa (TDP-43) |
| Q37164410 | Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity |
| Q28730723 | Aberrant localization of FUS and TDP43 is associated with misfolding of SOD1 in amyotrophic lateral sclerosis |
| Q43119425 | Accelerated disease onset with stabilized familial amyotrophic lateral sclerosis (ALS)-linked mutant TDP-43 proteins |
| Q45437620 | Acceleration of TDP43 and FUS/TLS protein expressions in the preconditioned hippocampus following repeated transient ischemia |
| Q55265811 | Active nuclear import and passive nuclear export are the primary determinants of TDP-43 localization. |
| Q42277252 | Adenoviral expression of TDP-43 and FUS genes and shRNAs for protein degradation pathways in rodent motoneurons in vitro and in vivo |
| Q58566479 | Age-related deregulation of TDP-43 after stroke enhances NF-κB-mediated inflammation and neuronal damage |
| Q35126200 | Allele-specific knockdown of ALS-associated mutant TDP-43 in neural stem cells derived from induced pluripotent stem cells |
| Q56531747 | Amyotrophic lateral sclerosis |
| Q64387024 | Amyotrophic lateral sclerosis-associated TDP-43 mutation Q331K prevents nuclear translocation of XRCC4-DNA ligase 4 complex and is linked to genome damage-mediated neuronal apoptosis |
| Q64096518 | An Intramolecular Salt Bridge Linking TDP43 RNA Binding, Protein Stability, and TDP43-Dependent Neurodegeneration |
| Q38301905 | An acetylation switch controls TDP-43 function and aggregation propensity |
| Q37223636 | An insoluble frontotemporal lobar degeneration-associated TDP-43 C-terminal fragment causes neurodegeneration and hippocampus pathology in transgenic mice |
| Q30537986 | Astrocyte pathology and the absence of non-cell autonomy in an induced pluripotent stem cell model of TDP-43 proteinopathy. |
| Q91708719 | Astrocytes with TDP-43 inclusions exhibit reduced noradrenergic cAMP and Ca2+ signaling and dysregulated cell metabolism |
| Q33575134 | Astrocytic TDP-43 pathology in Alexander disease |
| Q24297462 | Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS |
| Q43142752 | Autophagy meets fused in sarcoma-positive stress granules. |
| Q48161812 | Biochemical and histopathological alterations in TAR DNA-binding protein-43 after acute ischemic stroke in rats |
| Q50350613 | Biology and Pathobiology of TDP-43 and Emergent Therapeutic Strategies. |
| Q92488891 | Bridging biophysics and neurology: aberrant phase transitions in neurodegenerative disease |
| Q43096791 | CUL2-mediated clearance of misfolded TDP-43 is paradoxically affected by VHL in oligodendrocytes in ALS. |
| Q42739339 | Caspase-cleaved transactivation response DNA-binding protein 43 in Parkinson's disease and dementia with Lewy bodies |
| Q36098117 | Cdc37/Hsp90 protein complex disruption triggers an autophagic clearance cascade for TDP-43 protein |
| Q90349928 | Cell-to-cell transmission of C9orf72 poly-(Gly-Ala) triggers key features of ALS/FTD |
| Q41819989 | Cellular model of TAR DNA-binding protein 43 (TDP-43) aggregation based on its C-terminal Gln/Asn-rich region |
| Q57492611 | Characterization of TDP-43 RRM2 Partially Folded States and Their Significance to ALS Pathogenesis |
| Q42940304 | Characterization of alternative isoforms and inclusion body of the TAR DNA-binding protein-43. |
| Q38109705 | Co-localization of Bunina bodies and TDP-43 inclusions in lower motor neurons in amyotrophic lateral sclerosis |
| Q41916097 | Cognitive decline typical of frontotemporal lobar degeneration in transgenic mice expressing the 25-kDa C-terminal fragment of TDP-43. |
| Q47253485 | Comparative analysis of thermal unfolding simulations of RNA recognition motifs (RRMs) of TAR DNA-binding protein 43 (TDP-43). |
| Q36065980 | Comparison of parallel high-throughput RNA sequencing between knockout of TDP-43 and its overexpression reveals primarily nonreciprocal and nonoverlapping gene expression changes in the central nervous system of Drosophila |
| Q34541179 | Conserved acidic amino acid residues in a second RNA recognition motif regulate assembly and function of TDP-43. |
| Q58566969 | Control of CNS functions by RNA-binding proteins in neurological diseases |
| Q26863439 | Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis |
| Q37662585 | Cytoplasmic Relocalization of TAR DNA-Binding Protein 43 Is Not Sufficient to Reproduce Cellular Pathologies Associated with ALS In vitro. |
| Q33987984 | Cytoplasmic accumulation and aggregation of TDP-43 upon proteasome inhibition in cultured neurons |
| Q39811341 | Cytoplasmic accumulation of TDP-43 in circulating lymphomonocytes of ALS patients with and without TARDBP mutations |
| Q37530731 | Cytoplasmic inclusions of TDP-43 in neurodegenerative diseases: a potential role for caspases |
| Q36019592 | Cytoplasmic mislocalization of RNA splicing factors and aberrant neuronal gene splicing in TDP-43 transgenic pig brain. |
| Q33649745 | Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis |
| Q33614771 | Cytoplasmic poly-GA aggregates impair nuclear import of TDP-43 in C9orf72 ALS/FTLD. |
| Q39743300 | Cytoplasmic translocation, aggregation, and cleavage of TDP-43 by enteroviral proteases modulate viral pathogenesis |
| Q92060228 | Detection of TAR DNA-binding protein 43 (TDP-43) oligomers as initial intermediate species during aggregate formation |
| Q37098891 | Developmentally Regulated RNA-binding Protein 1 (Drb1)/RNA-binding Motif Protein 45 (RBM45), a Nuclear-Cytoplasmic Trafficking Protein, Forms TAR DNA-binding Protein 43 (TDP-43)-mediated Cytoplasmic Aggregates |
| Q48400372 | Differential expression of TAR DNA-binding protein (TDP-43) in the central nervous system of horses afflicted with equine motor neuron disease (EMND): a preliminary study of a potential pathologic marker. |
| Q30574024 | Differential roles of the ubiquitin proteasome system and autophagy in the clearance of soluble and aggregated TDP-43 species |
| Q51231308 | Dynamic mislocalizations of nuclear pore complex proteins after focal cerebral ischemia in rat. |
| Q47946104 | Dysregulated molecular pathways in amyotrophic lateral sclerosis-frontotemporal dementia spectrum disorder. |
| Q34519947 | Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice |
| Q34044401 | Elevated expression of TDP-43 in the forebrain of mice is sufficient to cause neurological and pathological phenotypes mimicking FTLD-U. |
| Q54943679 | Elimination of TDP-43 inclusions linked to amyotrophic lateral sclerosis by a misfolding-specific intrabody with dual proteolytic signals. |
| Q33618272 | Elucidating the genetics and pathology of Perry syndrome |
| Q48198417 | Essential role of hippocampal noradrenaline in the regulation of spatial working memory and tdp-43 tissue pathology. |
| Q37136781 | Expression of TDP-43 C-terminal Fragments in Vitro Recapitulates Pathological Features of TDP-43 Proteinopathies |
| Q39384099 | Familial Amyotrophic Lateral Sclerosis-linked Mutations in Profilin 1 Exacerbate TDP-43-induced Degeneration in the Retina of Drosophila melanogaster through an Increase in the Cytoplasmic Localization of TDP-43. |
| Q37653253 | Folding of the RNA recognition motif (RRM) domains of the amyotrophic lateral sclerosis (ALS)-linked protein TDP-43 reveals an intermediate state |
| Q52147386 | Folliculin, a tumor suppressor associated with Birt-Hogg-Dubé (BHD) syndrome, is a novel modifier of TDP-43 cytoplasmic translocation and aggregation. |
| Q33783811 | Formation and spreading of TDP-43 aggregates in cultured neuronal and glial cells demonstrated by time-lapse imaging |
| Q38382217 | Frontotemporal lobar degeneration: Pathogenesis, pathology and pathways to phenotype |
| Q37259106 | Functional mapping of the interaction between TDP-43 and hnRNP A2 in vivo |
| Q35773678 | Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration |
| Q42278719 | Genetic mutations in RNA-binding proteins and their roles in ALS. |
| Q34574931 | Genetics of frontotemporal lobar degeneration |
| Q51149826 | Heat Shock-induced Phosphorylation of TAR DNA-binding Protein 43 (TDP-43) by MAPK/ERK Kinase Regulates TDP-43 Function. |
| Q48906467 | Heterogeneity of Matrin 3 in the developing and aging murine central nervous system |
| Q39037865 | High content analysis in amyotrophic lateral sclerosis |
| Q38853070 | Human TDP-43 and FUS selectively affect motor neuron maturation and survival in a murine cell model of ALS by non-cell-autonomous mechanisms |
| Q27325625 | Hyperphosphorylation as a defense mechanism to reduce TDP-43 aggregation |
| Q60045141 | Identification of TCERG1 as a new genetic modulator of TDP-43 production in Drosophila |
| Q37816817 | Implications of the prion-related Q/N domains in TDP-43 and FUS. |
| Q48325589 | Increased cytoplasmic TDP-43 reduces global protein synthesis by interacting with RACK1 on polyribosomes |
| Q36434528 | Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models |
| Q34758540 | Inhibition of TDP-43 aggregation by nucleic acid binding |
| Q52911856 | Inositol Hexakisphosphate Kinase 2 Promotes Cell Death in Cells with Cytoplasmic TDP-43 Aggregation. |
| Q34074385 | Interaction with polyglutamine aggregates reveals a Q/N-rich domain in TDP-43. |
| Q48252631 | Keap1 is localized in neuronal and glial cytoplasmic inclusions in various neurodegenerative diseases |
| Q30492839 | Knockdown of transactive response DNA-binding protein (TDP-43) downregulates histone deacetylase 6 |
| Q30494776 | Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis |
| Q47661814 | Lost in Transportation: Nucleocytoplasmic Transport Defects in ALS and Other Neurodegenerative Diseases |
| Q35746425 | Low molecular weight species of TDP-43 generated by abnormal splicing form inclusions in amyotrophic lateral sclerosis and result in motor neuron death. |
| Q92534777 | Mechanisms of Immune Activation by c9orf72-Expansions in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia |
| Q30543660 | Modeling key pathological features of frontotemporal dementia with C9ORF72 repeat expansion in iPSC-derived human neurons |
| Q64263070 | Molecular Mechanisms of TDP-43 Misfolding and Pathology in Amyotrophic Lateral Sclerosis |
| Q37143159 | Molecular neuropathology of TDP-43 proteinopathies |
| Q37959310 | Molecular pathology and genetic advances in amyotrophic lateral sclerosis: an emerging molecular pathway and the significance of glial pathology |
| Q33739682 | Mutations in spliceosomal proteins and retina degeneration |
| Q28236796 | Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis |
| Q36638284 | Neurodegeneration the RNA way |
| Q34079770 | Neurodegenerative models in Drosophila: polyglutamine disorders, Parkinson disease, and amyotrophic lateral sclerosis |
| Q33932740 | Neuronal function and dysfunction of Drosophila dTDP |
| Q90234407 | Neurons selectively targeted in frontotemporal dementia reveal early stage TDP-43 pathobiology |
| Q39344391 | New routes in frontotemporal dementia drug discovery |
| Q33622382 | Novel monoclonal antibodies to normal and pathologically altered human TDP-43 proteins |
| Q28473603 | Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis |
| Q34094693 | Nuclear TAR DNA-binding protein 43: A new target for amyotrophic lateral sclerosis treatment |
| Q38460097 | Nuclear bodies: the emerging biophysics of nucleoplasmic phases |
| Q55038139 | Nuclear egress of TDP-43 and FUS occurs independently of Exportin-1/CRM1. |
| Q35910495 | Nuclear export inhibitors avert progression in preclinical models of inflammatory demyelination |
| Q38920545 | Nuclear trafficking in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. |
| Q38810478 | Nuclear transport dysfunction: a common theme in amyotrophic lateral sclerosis and frontotemporal dementia |
| Q52607544 | Nuclear transport impairment of amyotrophic lateral sclerosis-linked mutations in FUS/TLS. |
| Q60895956 | Nucleo-cytoplasmic transport of TDP-43 studied in real time: impaired microglia function leads to axonal spreading of TDP-43 in degenerating motor neurons |
| Q37028365 | Nucleocytoplasmic transport in C9orf72-mediated ALS/FTD. |
| Q35592875 | On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia |
| Q41319968 | Onset of disorder and protein aggregation due to oxidation-induced intermolecular disulfide bonds: case study of RRM2 domain from TDP-43. |
| Q89818887 | Optogenetic modulation of TDP-43 oligomerization accelerates ALS-related pathologies in the spinal motor neurons |
| Q38672664 | PERK-opathies: An Endoplasmic Reticulum Stress Mechanism Underlying Neurodegeneration |
| Q92258049 | Partial Failure of Proteostasis Systems Counteracting TDP-43 Aggregates in Neurodegenerative Diseases |
| Q38219206 | Pathogenesis/genetics of frontotemporal dementia and how it relates to ALS. |
| Q26828357 | Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD-ALS spectrum disorders |
| Q57476533 | Patient-derived frontotemporal lobar degeneration brain extracts induce formation and spreading of TDP-43 pathology in vivo |
| Q60938517 | Perturbations in Traffic: Aberrant Nucleocytoplasmic Transport at the Heart of Neurodegeneration |
| Q39901141 | Phosphorylated and ubiquitinated TDP-43 pathological inclusions in ALS and FTLD-U are recapitulated in SH-SY5Y cells |
| Q38803419 | Phosphorylation of TAR DNA-binding Protein of 43 kDa (TDP-43) by Truncated Casein Kinase 1δ Triggers Mislocalization and Accumulation of TDP-43. |
| Q30499509 | Phosphorylation promotes neurotoxicity in a Caenorhabditis elegans model of TDP-43 proteinopathy |
| Q41997710 | Potentiation of amyotrophic lateral sclerosis (ALS)-associated TDP-43 aggregation by the proteasome-targeting factor, ubiquilin 1. |
| Q37380181 | Prion-like nuclear aggregation of TDP-43 during heat shock is regulated by HSP40/70 chaperones |
| Q38922025 | Prion-like propagation as a pathogenic principle in frontotemporal dementia. |
| Q50074864 | Progranulin-mediated deficiency of cathepsin D results in FTD and NCL-like phenotypes in neurons derived from FTD patients |
| Q38065721 | Progress in frontotemporal dementia research |
| Q37954610 | Protein misdirection inside and outside motor neurons in Amyotrophic Lateral Sclerosis (ALS): a possible clue for therapeutic strategies |
| Q35061120 | Proteomic analysis reveals differentially regulated protein acetylation in human amyotrophic lateral sclerosis spinal cord |
| Q92063917 | Proteostasis Failure in Neurodegenerative Diseases: Focus on Oxidative Stress |
| Q39084550 | Proteostasis and Diseases of the Motor Unit. |
| Q38756528 | Quantification of the Relative Contributions of Loss-of-function and Gain-of-function Mechanisms in TAR DNA-binding Protein 43 (TDP-43) Proteinopathies |
| Q36099276 | RBM45 homo-oligomerization mediates association with ALS-linked proteins and stress granules |
| Q61811636 | RNA Dysregulation in Amyotrophic Lateral Sclerosis |
| Q58692328 | RNA-Binding Proteins in Amyotrophic Lateral Sclerosis |
| Q47569012 | RNA-binding proteins in neurodegeneration: mechanisms in aggregate |
| Q37216891 | RNA-mediated toxicity in neurodegenerative disease |
| Q90664241 | RRM adjacent TARDBP mutations disrupt RNA binding and enhance TDP-43 proteinopathy |
| Q24648173 | Rapamycin rescues TDP-43 mislocalization and the associated low molecular mass neurofilament instability |
| Q90378129 | Recapitulation of Pathological TDP-43 Features in Immortalized Lymphocytes from Sporadic ALS Patients |
| Q27308854 | Recruitment of the oncoprotein v-ErbA to aggresomes. |
| Q26750630 | Redox Imbalance and Viral Infections in Neurodegenerative Diseases |
| Q24300438 | Redox signalling directly regulates TDP-43 via cysteine oxidation and disulphide cross-linking |
| Q51148361 | Reduced stress granule formation and cell death in fibroblasts with the A382T mutation of TARDBP gene: evidence for loss of TDP-43 nuclear function. |
| Q35912453 | Regulation of nuclear TDP-43 by NR2A-containing NMDA receptors and PTEN. |
| Q58553466 | Reply: TDP-43 mutations increase HNRNP A1-7B through gain of splicing function |
| Q42110964 | Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNA-binding protein of 43 kDa (TDP-43) |
| Q34983534 | Reversible behavioral phenotypes in a conditional mouse model of TDP-43 proteinopathies |
| Q34642738 | Review: transactive response DNA-binding protein 43 (TDP-43): mechanisms of neurodegeneration |
| Q49571548 | Robustness and Vulnerability of the Autoregulatory System That Maintains Nuclear TDP-43 Levels: A Trade-off Hypothesis for ALS Pathology Based on in Silico Data. |
| Q35512201 | Rodent models of TDP-43 proteinopathy: investigating the mechanisms of TDP-43-mediated neurodegeneration |
| Q30541190 | Selective forelimb impairment in rats expressing a pathological TDP-43 25 kDa C-terminal fragment to mimic amyotrophic lateral sclerosis |
| Q38956576 | Short-term suppression of A315T mutant human TDP-43 expression improves functional deficits in a novel inducible transgenic mouse model of FTLD-TDP and ALS. |
| Q38601956 | Splicing factors act as genetic modulators of TDP-43 production in a new autoregulatory TDP-43 Drosophila model |
| Q92535116 | Structural Insights Into TDP-43 and Effects of Post-translational Modifications |
| Q47972820 | Structural Rearrangement upon Fragmentation of the Stability Core of the ALS-Linked Protein TDP-43. |
| Q35875836 | Studies of alternative isoforms provide insight into TDP-43 autoregulation and pathogenesis |
| Q42736731 | Sustained expression of TDP-43 and FUS in motor neurons in rodent's lifetime. |
| Q51814348 | TAR DNA-Binding protein 43 accumulation in protein aggregate myopathies. |
| Q33941040 | TAR DNA-binding protein 43 in neurodegenerative disease |
| Q34147753 | TAR DNA-binding protein 43 pathology in Alzheimer's disease with psychosis. |
| Q24594172 | TARDBP mutation analysis in TDP-43 proteinopathies and deciphering the toxicity of mutant TDP-43 |
| Q35842277 | TDP-43 Inhibits NF-κB Activity by Blocking p65 Nuclear Translocation |
| Q34831850 | TDP-43 N terminus encodes a novel ubiquitin-like fold and its unfolded form in equilibrium that can be shifted by binding to ssDNA |
| Q28080628 | TDP-43 Proteinopathy and ALS: Insights into Disease Mechanisms and Therapeutic Targets |
| Q27692111 | TDP-43 aggregation in neurodegeneration: are stress granules the key? |
| Q38743891 | TDP-43 aggregation mirrors TDP-43 knockdown, affecting the expression levels of a common set of proteins |
| Q36336278 | TDP-43 and FUS en route from the nucleus to the cytoplasm |
| Q28294001 | TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia |
| Q37733168 | TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration |
| Q39756986 | TDP-43 dimerizes in human cells in culture. |
| Q37904288 | TDP-43 functions and pathogenic mechanisms implicated in TDP-43 proteinopathies |
| Q34566756 | TDP-43 in aging and Alzheimer's disease - a review |
| Q36509977 | TDP-43 in central nervous system development and function: clues to TDP-43-associated neurodegeneration |
| Q57306362 | TDP-43 in neurodegenerative disorders |
| Q48693338 | TDP-43 in skeletal muscle of patients affected with amyotrophic lateral sclerosis. |
| Q37204062 | TDP-43 is a culprit in human neurodegeneration, and not just an innocent bystander |
| Q30427637 | TDP-43 is a transcriptional repressor: the testis-specific mouse acrv1 gene is a TDP-43 target in vivo |
| Q33342840 | TDP-43 is not a common cause of sporadic amyotrophic lateral sclerosis |
| Q41762388 | TDP-43 loss of cellular function through aggregation requires additional structural determinants beyond its C-terminal Q/N prion-like domain |
| Q33932237 | TDP-43 mediates degeneration in a novel Drosophila model of disease caused by mutations in VCP/p97. |
| Q47157167 | TDP-43 misexpression causes defects in dendritic growth |
| Q54251702 | TDP-43 regulates the alternative splicing of hnRNP A1 to yield an aggregation-prone variant in amyotrophic lateral sclerosis. |
| Q37813221 | TDP-43 toxicity in yeast |
| Q30493749 | TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration |
| Q37903412 | TDP-43: the relationship between protein aggregation and neurodegeneration in amyotrophic lateral sclerosis and frontotemporal lobar degeneration |
| Q55085029 | TDP43 nuclear export and neurodegeneration in models of amyotrophic lateral sclerosis and frontotemporal dementia. |
| Q28475724 | Tar DNA Binding Protein-43 (TDP-43) Associates with Stress Granules: Analysis of Cultured Cells and Pathological Brain Tissue |
| Q33786698 | The C-terminal TDP-43 fragments have a high aggregation propensity and harm neurons by a dominant-negative mechanism |
| Q38218666 | The ER mitochondria calcium cycle and ER stress response as therapeutic targets in amyotrophic lateral sclerosis. |
| Q41094549 | The N-terminal dimerization is required for TDP-43 splicing activity |
| Q64054884 | The Pathobiology of TDP-43 C-Terminal Fragments in ALS and FTLD |
| Q37855544 | The Relationship between Parkin and Protein Aggregation in Neurodegenerative Diseases |
| Q89497713 | The Role of RNA Binding Proteins for Local mRNA Translation: Implications in Neurological Disorders |
| Q54987435 | The Rules and Functions of Nucleocytoplasmic Shuttling Proteins. |
| Q34182046 | The aggregation and neurotoxicity of TDP-43 and its ALS-associated 25 kDa fragment are differentially affected by molecular chaperones in Drosophila |
| Q90295506 | The basis of clinicopathological heterogeneity in TDP-43 proteinopathy |
| Q37623715 | The chaperone HSPB8 reduces the accumulation of truncated TDP-43 species in cells and protects against TDP-43-mediated toxicity. |
| Q30541099 | The dual functions of the extreme N-terminus of TDP-43 in regulating its biological activity and inclusion formation |
| Q26751400 | The extreme N-terminus of TDP-43 mediates the cytoplasmic aggregation of TDP-43 and associated toxicity in vivo |
| Q26991684 | The function of RNA-binding proteins at the synapse: implications for neurodegeneration |
| Q40632646 | The heat shock response plays an important role in TDP-43 clearance: evidence for dysfunction in amyotrophic lateral sclerosis |
| Q57807406 | The impact of histone post-translational modifications in neurodegenerative diseases |
| Q37564674 | The molecular basis of frontotemporal dementia |
| Q37593727 | The molecular links between TDP-43 dysfunction and neurodegeneration |
| Q33847532 | The role of transactive response DNA-binding protein-43 in amyotrophic lateral sclerosis and frontotemporal dementia |
| Q92288067 | The secretion of the angiogenic and neurotrophic factor angiogenin is COPII and microtubule dependent |
| Q39369902 | The self-interaction of native TDP-43 C terminus inhibits its degradation and contributes to early proteinopathies. |
| Q36724968 | The truncated C-terminal RNA recognition motif of TDP-43 protein plays a key role in forming proteinaceous aggregates |
| Q26998919 | Therapeutic and diagnostic challenges for frontotemporal dementia |
| Q37355794 | Therapeutic effect of berberine on TDP-43-related pathogenesis in FTLD and ALS. |
| Q49823859 | Towards a TDP-43-Based Biomarker for ALS and FTLD. |
| Q35824582 | Transcriptomic Changes Due to Cytoplasmic TDP-43 Expression Reveal Dysregulation of Histone Transcripts and Nuclear Chromatin |
| Q50047147 | Traumatic injury induces Stress Granule Formation and enhances Motor Dysfunctions in ALS/FTD Models |
| Q36748388 | Two mutations G335D and Q343R within the amyloidogenic core region of TDP-43 influence its aggregation and inclusion formation |
| Q37205729 | Update on recent molecular and genetic advances in frontotemporal lobar degeneration |
| Q30655551 | Wild type human TDP-43 potentiates ALS-linked mutant TDP-43 driven progressive motor and cortical neuron degeneration with pathological features of ALS. |
| Q58582569 | Znf179 E3 ligase-mediated TDP-43 polyubiquitination is involved in TDP-43- ubiquitinated inclusions (UBI) (+)-related neurodegenerative pathology |
| Q55329393 | mTh1 driven expression of hTDP-43 results in typical ALS/FTLD neuropathological symptoms. |
| Q90276033 | mtDNA Activates cGAS Signaling and Suppresses the YAP-Mediated Endothelial Cell Proliferation Program to Promote Inflammatory Injury |
| Q39335734 | p62/sequestosome 1 binds to TDP-43 in brains with frontotemporal lobar degeneration with TDP-43 inclusions |
| Q28580544 | β-amyloid triggers ALS-associated TDP-43 pathology in AD models |
Search more.